PIM 447

Drug Profile

PIM 447

Alternative Names: LGH-447; Pan-pim inhibitor - Novartis Oncology; PIM447

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Myelofibrosis (Combination therapy) presented at the 58th Annual Meeting of the American Society of Hematology (ASH-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Spain (PO)
  • 01 May 2016 Novartis completes a phase I trial for Multiple myeloma (Second-line treatment or greater) in Japan (JapicCTI142589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top